Everest Medicines Ltd. 1952

Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) has approved CARDAMYST® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest's first innovative therapy approved in the car

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced its interim results for the first half of 2026 along with a corporate update.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2026, and provide a business update on Aug. 19, 2026. The Company will hold an online investor call on the same day.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will participate in the upcoming investor conferences.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that China's National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL® (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LD

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, which were approved by the National Medical Products Administration (NMPA) in December 2025.

Everest Medicines has signed an exclusive licensing agreement with Dimerix to develop and commercialize DMX-200 across Asia-Pacific. The deal focuses on treating serious kidney diseases such as focal segmental glomerulosclerosis, an area with significant unmet medical need. This agreement expands Everest Medicines' nephrology pipeline and reinforces its role as a regional player in kidney disease therapies. Everest Medicines (SEHK:1952) has entered this new agreement with Dimerix as the...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, Sou

LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China...

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, U.S. brand name VIZZ) in Greater China, including Chi

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today announced that Everest Medicines (HKEX1952, or “Everest”), has entered into an Asset Purc

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. ("Mabworks"), under which the Company has obtained exclusive rights for the clinical development and commercialization of Bejescin® (MIL62, Obinutuzumab beta Injection) across th

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine ki

SAN DIEGO, June 02, 2026--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.

Everest Medicines will pay $250m in three instalments: $150m at closing, two $50m payments in 2028, 2029.